UnitedHealth says it is facing DOJ investigation over Medicare billing practices

UnitedHealth Group (UNH) disclosed a Justice Department investigation into its Medicare billing practices, encompassing both criminal and civil requests, causing its shares to drop nearly 4% premarket. This probe intensifies scrutiny on UNH's Medicare Advantage business, its largest revenue segment, which has been previously flagged for inflated diagnoses. While UNH expressed confidence in its practices and initiated a third-party review, this development adds to a series of recent operational setbacks for the healthcare giant.

Analysis

UnitedHealth Group (UNH) has officially confirmed it is under a Justice Department investigation, encompassing both criminal and civil inquiries into its Medicare billing practices. This disclosure, which prompted a nearly 4% premarket share price decline, elevates the legal and regulatory risk for the company's largest and most critical business segment, Medicare and retirement, which generated $139 billion in revenue last year. While the company expressed confidence in its practices, pointing to favorable independent audits and a prior special master's recommendation, it has also initiated a third-party review expected to conclude by the end of the third quarter. This development compounds a series of significant operational and reputational challenges for UNH, including a more than 42% year-to-date stock decline, the suspension of its 2025 forecast due to rising medical costs, a surprise CEO departure, and a major cyberattack. The investigation into potential Medicare Advantage overbilling now represents a tangible financial and governance overhang on a company already navigating a period of intense turmoil.

Key Decisions for Investors

• Investors should re-evaluate their risk exposure to UNH, as the formal DOJ investigation into its primary revenue driver introduces the potential for significant financial penalties and mandated changes to its business model.
• Closely monitor the progress and outcome of the company's internal third-party review, due by the end of Q3, as its findings will be a critical catalyst and a key indicator of the potential severity of the issues.
• Consider the current legal issues not in isolation but within the context of the stock's 42% YTD decline and other recent setbacks, such as suspended guidance and management changes, to assess if this reflects a pattern of systemic risk rather than a one-off event.